HIV-encoded chemoattractant

Details HIV-encoded chemoattractant HIV-encoded chemoattractant

2005-04-12

2005-04-12

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S350000, C530S300000, C530S205000, C530S208000, C530S333000

Reexamination Certificate

active

06878685

ABSTRACT:
The combination of HIV proteins Tat and Nef is chemotactic for CD4+ cells. Utilizing the capacity of Tat and Nef to modulate CD4+ cell trafficking and infiltration, the invention provides various treatment modes for individuals infected with HIV. The invention further provides treatment modes for other localized diseases by controlling CD4+ cell trafficking and infiltration. In particular, the invention provides methodology for promoting CD4+ cell chemotaxis to a localized site of infection as a means of augmenting the efficacy of extant chemotherapeutic methods. The invention further provides methodology for diverting CD4+ cell infiltration from a localized site where the presence of CD4+ cells is detrimental to the clinical outcome, by providing a composition comprising Tat and Nef at a distinct site, such as blood, within the individual where the accumulation of CD4+ cells is less detrimental.

REFERENCES:
patent: 5159002 (1992-10-01), Pandey
patent: 5320094 (1994-06-01), Laube et al.
patent: 5428023 (1995-06-01), Russell-Jones et al.
patent: 5574018 (1996-11-01), Habberfield et al.
patent: 5606026 (1997-02-01), Rodman
patent: 5747526 (1998-05-01), Hollinshead
patent: 5891994 (1999-04-01), Goldstein
patent: 5968514 (1999-10-01), Johnson et al.
patent: 9325221 (1993-12-01), None
Joseph et al. FEBE Letters 2003, vol. 548, pp. 37-42.*
Kestler et al. Cell 1991, vol. 65, No. 4, pp. 651-662.*
Popik et al. J. Virol. 1994, vol. 68, No. 3, pp. 1324-1333.*
Skelton et al. Biochemistry 1995, vol. 34, pp. 5329-5324.*
Ylisastigue et al. AIDS 1998, vol. 12, pp. 977-984.*
Shepard et al. Nature 1981, vol. 294, pp. 563-565.*
Hinkula et al. J. Virol. 1997, vol. 71, pp. 5528-5539.*
Kedzierska et al. AIDS 2001, vol. 15, pp. 945-955.*
Petit et al. Virol. 2001, vol. 286, pp. 225-236.*
Chun et al.; Induction of HIV-1 replication . . . ; J. Exp. Med.; vol. 188, No. 1; pp. 83-91, Jul. 1998.*
Gait et al.; Progress in anti-HIV structure-based drug design; TIBTECH; vol. 13; pp. 430-438, Oct. 1995.*
R. Lafrenie et al., “HIV 1 Tat protein promotes chemotaxis and invasive behaviour by monocytes”, J. Immunol. vol. 157, 1996 pp. 974-977, XP000929467.
A. Albini et al., “HIV-1 Tat protein mimicry of chemokines”, Proc. Natl. Acad. Sci. USA, vol. 95, 1998 pp. 13153-13158, XP002146039.
D. Shutt et al., “HIV-induced T cell syncytia release a two-component T helper cell chemoattractant composed Of Nef and Tat”, J. Cell Sci., vol. 112, 1999 pp. 3931-3941, XP000938498.
Benichou et al.; “Physical Interaction of the HIV-1 Nef Protein with β-COP, a Component of Non-clathrin-coated Vesicles Essential for Membrane Traffic”; The Journal of Biological Chemistry; vol. 269, No. 48; Dec. 2, 1994; pp. 30073-30076.
Beger et al.; “Reconsidering Targeted Toxins to Eliminate HIV Infection: You Gotta Have HAART”; Proc. Natl. Acad. Sci. USA; vol. 95; Sep. 1998; pp. 11511-11513.
Boyden; “The Chemotactic Effect of Mixtures of Antibody and Antigen on Polymorphoneclear Leucocytes”; Aug. 1961; pp. 453-466.
Center et al.; “Interleukin 16 and Its Function as a CD4 Ligand”; Immunology Today; vol. 17, No. 10; Oct. 1996; pp. 466-481.
Chen et al.; Intracellular Antibodies as a New Class of Therapeutic Molecules for Gene Therapy; Human Gene Therapy; vol. 5,; 1994; pp. 595-601.
Teixeira et al.; “Cytokine Profile Associated to Effector Functions of Human T Cell Clones Specific forSchistosoma mansoniAntigens”; Human Immunology; vol. 59; 1998; pp. 219-224.
Chun et al.; “Induction of HIV-1 Replication in Latently Infected CD4+T Cells Using a Combination of Cytokines”; The Journal of Experimental Medicine; vol. 188, No. 1; Jul. 6, 1998; pp. 83-91.
Clerici et al.; “A TH1→TH2 Switch is A Critical Step in the Etiology of HIV Infection”; Immunology Today; vol. 14, No. 3; 1993; pp. 107-111.
Desmedt et al.; “Macrophages Induce Cellular Immunity by Activating Th1 Cell Responses and Suppressing Th2 Cell Responses1”; The Journal of Immunology; 1998; pp. 5300-5308.
Frankel et al.; “Replication of HIV-1 in Dendritic Cell-Derived Syncytia at the Mucosal Surface of the Adenoid”; Science; vol. 272; Apr. 5, 1996; pp. 115-117.
Gratton et al.; “Molecular Analysis of the Cytoplasmic Domain of Cd4”; The Journal of Immunology; 1996; pp. 3305-3311.
Huffnagle et al.; “The Role of Monocyte Chemotactic Protein-1 (MCP-1) in the Recruitment of Monocytes and CD4+T Cells During a PulmonaryCryptococcus neoformansInfection1”; The Journal of Immunology; 1995; pp. 4790-4797.
Kowalski et al.; “functional Regions of the Envelope glycoprotein of Human Immunodeficiency Virus Type 1”; Reports; Sep. 11, 1987; pp. 1351-1355.
Levy; “Pathogenesis of Human Immunodeficiency Virus Infection”; Microbiological Reviews; vol. 57, No. 1; Mar. 1993; pp. 183-289.
Lifson et al.; Induction of CD4-dependent Cell Fusion by the HTLV-III LAV Envelope Glycoprotein; Letters to Nature; vol. 323; Oct. 23, 1986; pp. 725-728.
Lifson et al.; “AIDS Retrovirus Induced Cytopathology; Giant Cell formation and Involvement of CD4 Antigen”; Reports; May 30, 1986; pp. 1123-1127.
McCutcheon; “Chemotaxis in Leukocytes”; Physiological Reviews; vol. 26, No. 3; Jul. 1946; pp. 319-336.
McDougal et al.; “Binding of HTLV-III/LAV to T4+T Cells by a Complex of the 110K Viral Protein and the T4 Molecule”; Science; vol. 231; Jan. 24, 1986; pp. 382-385.
Smith et al.; “Monoclonal Antibody and Enzymatic Profiles of Human Malignant T-Lymphoid Cells and Derived Cell Lines1”; Cancer Research; vol. 44; Dec. 1984; pp. 5657-5660.
Miedema; “Immunological Abnormalities in the Natural History of HIV Infection: Mechanisms and Clinical Relevance”; Immunodeficiency Reviews; vol. 3; 1992; pp. 173-193.
Murphy et al.; “Human RANTES Induces the Migration of Human T Lymphocetes into the Peripheral Tissues of Mice with Severe Combined Immune Deficiency”; Eur. Journal of Immunology; vol. 24; 1994; pp. 1823-1827.
Otake et al.; “The Carboxyl-Terminal Region of HIV-1 Nef Protein is a Cell Surface Domain that can Interact with CD4+T Cells”; The Journal of Immunology; 1994; pp. 5826-5837.
Proost et al.; “The Role of Chemokines in Inflammation”; Review; vol. 26; 1996; pp. 211-223.
Rhodes; “Measurement of Chemotaxis in Boyden Chamber Filter Assays, is the Checkerboard Correction Valid?”; Journal of Immunology Methods; vol. 49; 1982; pp. 235-236.
Richman et al.; “The Impact of the Syncytium-Inducing Phenotype of Human Immunodeficiency Virus on Disease Progression”; The Journal of Infectious Diseases; vol. 169; 1994; pp. 968-974.
Ryan et al.; “The CD4-associated Tyrosine Kinase p56lckIs Required for Lymphocyte Chemoattractant Factor-induced T Lymphocyte Migration”; The Journal of Biological Chemistry; vol. 270, No. 29; Jul. 21, 1995; pp. 17081-17086.
Maniatis et al.; “Molecular Cloning”; A Laboratory Manual; 1982; 2 Sheets.
Schneider et al.; “Shedding and Interspecies Type Sero-reactivity of the Envelope Glycopolypeptide gp120 of the Human Immunodeficiency Virus”; J. Gen. Virol.; vol. 67; 1986; pp. 2533-2538.
Coffman; “Regulation of Immunity to Parasites by T Cells and T Cell-Derived Cytokines1”; Annu. Rec. Immunology; vol. 10; 1992; pp. 385-409.
Shutt et al.; “HIV-Induced Syncytia in Peripheral Blood Cell Cultures Crawl by Extending Giant Pseudopods”; Cellular Immunology; vol. 166; 1995; pp. 261-274.
Shutt et al.; “T Cell Syncytia Induced by HIV Release”; Journal of Cell Science; vol. 111, No. 1; Jan. 1998; pp. 99-109.
Soll; “The Use of Computers in Understanding How Animal Cells Crawl”; International Review of Cytology; vol. 163; 1995; pp. 43-104.
Standiford; “Cytokines and Pulmonary Host Defenses”; Journal of Infectious Diseases; vol. 3; 1997; pp. 81-88.
Sylwester et al.; “

Affiliated with

Also associated with

Rating

HIV-encoded chemoattractant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV-encoded chemoattractant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-encoded chemoattractant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3392348